nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—MAPK14—hematologic cancer	0.33	1	CbGaD
Etoricoxib—MAPK14—Nilotinib—hematologic cancer	0.0787	0.189	CbGbCtD
Etoricoxib—MAPK14—Dasatinib—hematologic cancer	0.0695	0.167	CbGbCtD
Etoricoxib—PTGS2—Lenalidomide—hematologic cancer	0.02	0.0479	CbGbCtD
Etoricoxib—CYP1A2—Anagrelide—hematologic cancer	0.0109	0.0261	CbGbCtD
Etoricoxib—PTGS2—Thalidomide—hematologic cancer	0.0107	0.0256	CbGbCtD
Etoricoxib—PTGS2—Triamcinolone—hematologic cancer	0.0074	0.0177	CbGbCtD
Etoricoxib—CYP2E1—Thalidomide—hematologic cancer	0.00696	0.0167	CbGbCtD
Etoricoxib—CYP2C9—Bexarotene—hematologic cancer	0.00679	0.0163	CbGbCtD
Etoricoxib—PTGS2—Betamethasone—hematologic cancer	0.00635	0.0152	CbGbCtD
Etoricoxib—CYP2E1—Dacarbazine—hematologic cancer	0.00598	0.0144	CbGbCtD
Etoricoxib—CYP2D6—Lomustine—hematologic cancer	0.00577	0.0138	CbGbCtD
Etoricoxib—CYP1A2—Carmustine—hematologic cancer	0.00571	0.0137	CbGbCtD
Etoricoxib—CYP2C9—Idarubicin—hematologic cancer	0.00563	0.0135	CbGbCtD
Etoricoxib—CYP2D6—Idarubicin—hematologic cancer	0.00515	0.0123	CbGbCtD
Etoricoxib—CYP2C19—Bortezomib—hematologic cancer	0.00501	0.012	CbGbCtD
Etoricoxib—CYP1A2—Methoxsalen—hematologic cancer	0.00486	0.0116	CbGbCtD
Etoricoxib—CYP2E1—Mitoxantrone—hematologic cancer	0.00464	0.0111	CbGbCtD
Etoricoxib—CYP1A2—Bortezomib—hematologic cancer	0.00462	0.0111	CbGbCtD
Etoricoxib—PTGS2—Cisplatin—hematologic cancer	0.00457	0.011	CbGbCtD
Etoricoxib—PTGS2—Etoposide—hematologic cancer	0.00449	0.0108	CbGbCtD
Etoricoxib—CYP1A2—Daunorubicin—hematologic cancer	0.00442	0.0106	CbGbCtD
Etoricoxib—CYP2D6—Hydroxyurea—hematologic cancer	0.00438	0.0105	CbGbCtD
Etoricoxib—CYP2C19—Thalidomide—hematologic cancer	0.00436	0.0105	CbGbCtD
Etoricoxib—CYP1A2—Alitretinoin—hematologic cancer	0.00433	0.0104	CbGbCtD
Etoricoxib—CYP2C9—Bortezomib—hematologic cancer	0.00416	0.00998	CbGbCtD
Etoricoxib—CYP2C19—Teniposide—hematologic cancer	0.00416	0.00998	CbGbCtD
Etoricoxib—CYP1A2—Thalidomide—hematologic cancer	0.00403	0.00965	CbGbCtD
Etoricoxib—CYP3A4—Bexarotene—hematologic cancer	0.00395	0.00947	CbGbCtD
Etoricoxib—CYP2C19—Ifosfamide—hematologic cancer	0.00384	0.00921	CbGbCtD
Etoricoxib—CYP2D6—Bortezomib—hematologic cancer	0.00381	0.00913	CbGbCtD
Etoricoxib—PTGS2—Dexamethasone—hematologic cancer	0.00369	0.00885	CbGbCtD
Etoricoxib—CYP3A4—Busulfan—hematologic cancer	0.00367	0.0088	CbGbCtD
Etoricoxib—CYP3A4—Lomustine—hematologic cancer	0.00367	0.0088	CbGbCtD
Etoricoxib—CYP2C19—Imatinib—hematologic cancer	0.00367	0.0088	CbGbCtD
Etoricoxib—CYP2C9—Thalidomide—hematologic cancer	0.00363	0.0087	CbGbCtD
Etoricoxib—CYP1A2—Dacarbazine—hematologic cancer	0.00346	0.0083	CbGbCtD
Etoricoxib—CYP2C9—Teniposide—hematologic cancer	0.00346	0.0083	CbGbCtD
Etoricoxib—CYP1A2—Imatinib—hematologic cancer	0.00339	0.00812	CbGbCtD
Etoricoxib—CYP3A4—Thiotepa—hematologic cancer	0.00327	0.00785	CbGbCtD
Etoricoxib—CYP2C9—Ifosfamide—hematologic cancer	0.00319	0.00766	CbGbCtD
Etoricoxib—PTGS2—ovarian follicle—hematologic cancer	0.00316	0.216	CbGeAlD
Etoricoxib—CYP2C9—Imatinib—hematologic cancer	0.00305	0.00731	CbGbCtD
Etoricoxib—CYP2E1—Etoposide—hematologic cancer	0.00293	0.00702	CbGbCtD
Etoricoxib—CYP2D6—Imatinib—hematologic cancer	0.00279	0.00669	CbGbCtD
Etoricoxib—CYP2C9—Nilotinib—hematologic cancer	0.00277	0.00665	CbGbCtD
Etoricoxib—CYP1A2—Dasatinib—hematologic cancer	0.00272	0.00652	CbGbCtD
Etoricoxib—CYP3A4—Methoxsalen—hematologic cancer	0.00254	0.0061	CbGbCtD
Etoricoxib—CYP2D6—Nilotinib—hematologic cancer	0.00253	0.00608	CbGbCtD
Etoricoxib—CYP2D6—Vinorelbine—hematologic cancer	0.00251	0.00603	CbGbCtD
Etoricoxib—CYP3A4—Bortezomib—hematologic cancer	0.00242	0.0058	CbGbCtD
Etoricoxib—CYP2C19—Prednisone—hematologic cancer	0.00242	0.0058	CbGbCtD
Etoricoxib—CYP2E1—Dexamethasone—hematologic cancer	0.00241	0.00577	CbGbCtD
Etoricoxib—CYP3A4—Daunorubicin—hematologic cancer	0.00232	0.00555	CbGbCtD
Etoricoxib—CYP3A4—Cytarabine—hematologic cancer	0.00204	0.0049	CbGbCtD
Etoricoxib—CYP3A4—Teniposide—hematologic cancer	0.00201	0.00482	CbGbCtD
Etoricoxib—CYP3A4—Ifosfamide—hematologic cancer	0.00186	0.00445	CbGbCtD
Etoricoxib—CYP3A4—Imatinib—hematologic cancer	0.00177	0.00425	CbGbCtD
Etoricoxib—CYP1A2—Etoposide—hematologic cancer	0.00169	0.00406	CbGbCtD
Etoricoxib—CYP3A4—Ruxolitinib—hematologic cancer	0.00167	0.004	CbGbCtD
Etoricoxib—CYP3A4—Nilotinib—hematologic cancer	0.00161	0.00386	CbGbCtD
Etoricoxib—CYP3A4—Vinorelbine—hematologic cancer	0.0016	0.00383	CbGbCtD
Etoricoxib—CYP2C9—Cisplatin—hematologic cancer	0.00155	0.00372	CbGbCtD
Etoricoxib—CYP2D6—Vinblastine—hematologic cancer	0.00155	0.00371	CbGbCtD
Etoricoxib—CYP2C19—Dexamethasone—hematologic cancer	0.00151	0.00362	CbGbCtD
Etoricoxib—CYP3A4—Triamcinolone—hematologic cancer	0.00146	0.0035	CbGbCtD
Etoricoxib—CYP3A4—Dasatinib—hematologic cancer	0.00142	0.00342	CbGbCtD
Etoricoxib—CYP3A4—Mitoxantrone—hematologic cancer	0.00141	0.00337	CbGbCtD
Etoricoxib—MAPK14—hematopoietic system—hematologic cancer	0.00133	0.0907	CbGeAlD
Etoricoxib—CYP2C9—Dexamethasone—hematologic cancer	0.00125	0.00301	CbGbCtD
Etoricoxib—CYP3A4—Betamethasone—hematologic cancer	0.00125	0.00301	CbGbCtD
Etoricoxib—CYP3A4—Prednisolone—hematologic cancer	0.00124	0.00297	CbGbCtD
Etoricoxib—CYP3A4—Prednisone—hematologic cancer	0.00117	0.0028	CbGbCtD
Etoricoxib—CYP2D6—Dexamethasone—hematologic cancer	0.00115	0.00275	CbGbCtD
Etoricoxib—CYP3A4—Irinotecan—hematologic cancer	0.00111	0.00266	CbGbCtD
Etoricoxib—CYP3A4—Vinblastine—hematologic cancer	0.000985	0.00236	CbGbCtD
Etoricoxib—Celecoxib—MAPK14—hematologic cancer	0.000968	0.299	CrCbGaD
Etoricoxib—CYP3A4—Vincristine—hematologic cancer	0.000968	0.00232	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—hematologic cancer	0.000952	0.00228	CbGbCtD
Etoricoxib—CYP3A4—Etoposide—hematologic cancer	0.000887	0.00213	CbGbCtD
Etoricoxib—MAPK14—blood—hematologic cancer	0.000879	0.0601	CbGeAlD
Etoricoxib—Vemurafenib—BRAF—hematologic cancer	0.000866	0.268	CrCbGaD
Etoricoxib—MAPK14—bone marrow—hematologic cancer	0.00085	0.0581	CbGeAlD
Etoricoxib—MAPK14—lung—hematologic cancer	0.00077	0.0527	CbGeAlD
Etoricoxib—CYP3A4—Dexamethasone—hematologic cancer	0.000729	0.00175	CbGbCtD
Etoricoxib—MAPK14—testis—hematologic cancer	0.000727	0.0497	CbGeAlD
Etoricoxib—CYP3A4—Doxorubicin—hematologic cancer	0.000605	0.00145	CbGbCtD
Etoricoxib—CYP2C19—hematopoietic system—hematologic cancer	0.000564	0.0385	CbGeAlD
Etoricoxib—MAPK14—lymph node—hematologic cancer	0.000527	0.036	CbGeAlD
Etoricoxib—CYP1A2—hematopoietic system—hematologic cancer	0.00046	0.0315	CbGeAlD
Etoricoxib—CYP2C9—hematopoietic system—hematologic cancer	0.000437	0.0299	CbGeAlD
Etoricoxib—CYP2E1—hematopoietic system—hematologic cancer	0.000414	0.0283	CbGeAlD
Etoricoxib—Celecoxib—CA9—hematologic cancer	0.000392	0.121	CrCbGaD
Etoricoxib—Vemurafenib—ABCG2—hematologic cancer	0.000385	0.119	CrCbGaD
Etoricoxib—PTGS2—hematopoietic system—hematologic cancer	0.000381	0.0261	CbGeAlD
Etoricoxib—CYP2C19—blood—hematologic cancer	0.000373	0.0255	CbGeAlD
Etoricoxib—CYP3A4—hematopoietic system—hematologic cancer	0.000333	0.0228	CbGeAlD
Etoricoxib—CYP2D6—hematopoietic system—hematologic cancer	0.000328	0.0224	CbGeAlD
Etoricoxib—CYP1A2—blood—hematologic cancer	0.000305	0.0209	CbGeAlD
Etoricoxib—CYP2C9—blood—hematologic cancer	0.00029	0.0198	CbGeAlD
Etoricoxib—CYP2E1—blood—hematologic cancer	0.000274	0.0188	CbGeAlD
Etoricoxib—CYP1A2—lung—hematologic cancer	0.000267	0.0183	CbGeAlD
Etoricoxib—PTGS2—blood—hematologic cancer	0.000253	0.0173	CbGeAlD
Etoricoxib—PTGS2—bone marrow—hematologic cancer	0.000244	0.0167	CbGeAlD
Etoricoxib—CYP2E1—lung—hematologic cancer	0.000241	0.0164	CbGeAlD
Etoricoxib—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	0.000239	0.209	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	0.000239	0.209	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	0.000234	0.205	CbGdCrCtD
Etoricoxib—CYP2E1—testis—hematologic cancer	0.000227	0.0155	CbGeAlD
Etoricoxib—PTGS2—lung—hematologic cancer	0.000221	0.0151	CbGeAlD
Etoricoxib—CYP3A4—blood—hematologic cancer	0.000221	0.0151	CbGeAlD
Etoricoxib—CYP2D6—blood—hematologic cancer	0.000217	0.0149	CbGeAlD
Etoricoxib—Vismodegib—ABCG2—hematologic cancer	0.000194	0.0599	CrCbGaD
Etoricoxib—CYP2D6—testis—hematologic cancer	0.00018	0.0123	CbGeAlD
Etoricoxib—Vemurafenib—ALB—hematologic cancer	0.000168	0.0519	CrCbGaD
Etoricoxib—PTGS2—lymph node—hematologic cancer	0.000151	0.0104	CbGeAlD
Etoricoxib—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	0.000144	0.126	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	0.000144	0.126	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	0.000141	0.124	CbGdCrCtD
Etoricoxib—Celecoxib—ALB—hematologic cancer	9.86e-05	0.0305	CrCbGaD
Etoricoxib—Vismodegib—ALB—hematologic cancer	8.45e-05	0.0261	CrCbGaD
Etoricoxib—Vismodegib—ABCB1—hematologic cancer	8.06e-05	0.0249	CrCbGaD
Etoricoxib—Dyspepsia—Betamethasone—hematologic cancer	1.1e-05	7.4e-05	CcSEcCtD
Etoricoxib—Urinary tract disorder—Doxorubicin—hematologic cancer	1.09e-05	7.37e-05	CcSEcCtD
Etoricoxib—Urticaria—Triamcinolone—hematologic cancer	1.09e-05	7.36e-05	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—hematologic cancer	1.09e-05	7.35e-05	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—hematologic cancer	1.09e-05	7.34e-05	CcSEcCtD
Etoricoxib—Asthenia—Etoposide—hematologic cancer	1.09e-05	7.33e-05	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—hematologic cancer	1.09e-05	7.33e-05	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisone—hematologic cancer	1.09e-05	7.32e-05	CcSEcCtD
Etoricoxib—Oedema—Prednisone—hematologic cancer	1.09e-05	7.32e-05	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—hematologic cancer	1.09e-05	7.32e-05	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—hematologic cancer	1.09e-05	7.31e-05	CcSEcCtD
Etoricoxib—Decreased appetite—Dexamethasone—hematologic cancer	1.09e-05	7.31e-05	CcSEcCtD
Etoricoxib—Decreased appetite—Betamethasone—hematologic cancer	1.09e-05	7.31e-05	CcSEcCtD
Etoricoxib—Nausea—Mitoxantrone—hematologic cancer	1.08e-05	7.3e-05	CcSEcCtD
Etoricoxib—Nausea—Irinotecan—hematologic cancer	1.08e-05	7.3e-05	CcSEcCtD
Etoricoxib—Immune system disorder—Epirubicin—hematologic cancer	1.08e-05	7.28e-05	CcSEcCtD
Etoricoxib—Infection—Prednisone—hematologic cancer	1.08e-05	7.28e-05	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—hematologic cancer	1.08e-05	7.27e-05	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.08e-05	7.26e-05	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.08e-05	7.26e-05	CcSEcCtD
Etoricoxib—Fatigue—Dexamethasone—hematologic cancer	1.08e-05	7.25e-05	CcSEcCtD
Etoricoxib—Fatigue—Betamethasone—hematologic cancer	1.08e-05	7.25e-05	CcSEcCtD
Etoricoxib—Pruritus—Etoposide—hematologic cancer	1.07e-05	7.23e-05	CcSEcCtD
Etoricoxib—Shock—Prednisone—hematologic cancer	1.07e-05	7.21e-05	CcSEcCtD
Etoricoxib—Arrhythmia—Epirubicin—hematologic cancer	1.07e-05	7.2e-05	CcSEcCtD
Etoricoxib—Pain—Dexamethasone—hematologic cancer	1.07e-05	7.19e-05	CcSEcCtD
Etoricoxib—Pain—Betamethasone—hematologic cancer	1.07e-05	7.19e-05	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—hematologic cancer	1.07e-05	7.19e-05	CcSEcCtD
Etoricoxib—Nervous system disorder—Prednisone—hematologic cancer	1.07e-05	7.18e-05	CcSEcCtD
Etoricoxib—Alopecia—Epirubicin—hematologic cancer	1.06e-05	7.12e-05	CcSEcCtD
Etoricoxib—Skin disorder—Prednisone—hematologic cancer	1.06e-05	7.11e-05	CcSEcCtD
Etoricoxib—Nausea—Gemcitabine—hematologic cancer	1.06e-05	7.11e-05	CcSEcCtD
Etoricoxib—Vomiting—Cisplatin—hematologic cancer	1.05e-05	7.09e-05	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—hematologic cancer	1.05e-05	7.07e-05	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—hematologic cancer	1.05e-05	7.06e-05	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—hematologic cancer	1.05e-05	7.05e-05	CcSEcCtD
Etoricoxib—Rash—Cisplatin—hematologic cancer	1.04e-05	7.03e-05	CcSEcCtD
Etoricoxib—Dermatitis—Cisplatin—hematologic cancer	1.04e-05	7.03e-05	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—hematologic cancer	1.04e-05	7.02e-05	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—hematologic cancer	1.04e-05	7.02e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Etoposide—hematologic cancer	1.04e-05	6.99e-05	CcSEcCtD
Etoricoxib—Anorexia—Prednisone—hematologic cancer	1.04e-05	6.98e-05	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—hematologic cancer	1.04e-05	6.97e-05	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—hematologic cancer	1.03e-05	6.96e-05	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—hematologic cancer	1.03e-05	6.93e-05	CcSEcCtD
Etoricoxib—Feeling abnormal—Betamethasone—hematologic cancer	1.03e-05	6.93e-05	CcSEcCtD
Etoricoxib—Feeling abnormal—Dexamethasone—hematologic cancer	1.03e-05	6.93e-05	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—hematologic cancer	1.03e-05	6.92e-05	CcSEcCtD
Etoricoxib—Cardiac disorder—Doxorubicin—hematologic cancer	1.03e-05	6.92e-05	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—hematologic cancer	1.03e-05	6.92e-05	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.02e-05	6.88e-05	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Betamethasone—hematologic cancer	1.02e-05	6.88e-05	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—hematologic cancer	1.02e-05	6.87e-05	CcSEcCtD
Etoricoxib—Hypersensitivity—Triamcinolone—hematologic cancer	1.01e-05	6.83e-05	CcSEcCtD
Etoricoxib—Angiopathy—Doxorubicin—hematologic cancer	1.01e-05	6.77e-05	CcSEcCtD
Etoricoxib—Dizziness—Etoposide—hematologic cancer	1e-05	6.76e-05	CcSEcCtD
Etoricoxib—Muscle spasms—Epirubicin—hematologic cancer	1e-05	6.75e-05	CcSEcCtD
Etoricoxib—Immune system disorder—Doxorubicin—hematologic cancer	1e-05	6.74e-05	CcSEcCtD
Etoricoxib—Mediastinal disorder—Doxorubicin—hematologic cancer	9.99e-06	6.72e-05	CcSEcCtD
Etoricoxib—Urticaria—Betamethasone—hematologic cancer	9.93e-06	6.68e-05	CcSEcCtD
Etoricoxib—Urticaria—Dexamethasone—hematologic cancer	9.93e-06	6.68e-05	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Prednisone—hematologic cancer	9.91e-06	6.67e-05	CcSEcCtD
Etoricoxib—Dizziness—Prednisolone—hematologic cancer	9.9e-06	6.67e-05	CcSEcCtD
Etoricoxib—Arrhythmia—Doxorubicin—hematologic cancer	9.9e-06	6.66e-05	CcSEcCtD
Etoricoxib—Asthenia—Triamcinolone—hematologic cancer	9.88e-06	6.65e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Dexamethasone—hematologic cancer	9.88e-06	6.65e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Betamethasone—hematologic cancer	9.88e-06	6.65e-05	CcSEcCtD
Etoricoxib—Nausea—Cisplatin—hematologic cancer	9.84e-06	6.63e-05	CcSEcCtD
Etoricoxib—Insomnia—Prednisone—hematologic cancer	9.84e-06	6.62e-05	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—hematologic cancer	9.83e-06	6.61e-05	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—hematologic cancer	9.79e-06	6.59e-05	CcSEcCtD
Etoricoxib—Pruritus—Triamcinolone—hematologic cancer	9.74e-06	6.56e-05	CcSEcCtD
Etoricoxib—Cough—Methotrexate—hematologic cancer	9.72e-06	6.54e-05	CcSEcCtD
Etoricoxib—Mental disorder—Doxorubicin—hematologic cancer	9.71e-06	6.54e-05	CcSEcCtD
Etoricoxib—Vomiting—Etoposide—hematologic cancer	9.65e-06	6.5e-05	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—hematologic cancer	9.65e-06	6.49e-05	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—hematologic cancer	9.65e-06	6.49e-05	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—hematologic cancer	9.64e-06	6.49e-05	CcSEcCtD
Etoricoxib—Agitation—Epirubicin—hematologic cancer	9.58e-06	6.45e-05	CcSEcCtD
Etoricoxib—Dyspepsia—Prednisone—hematologic cancer	9.58e-06	6.45e-05	CcSEcCtD
Etoricoxib—Rash—Etoposide—hematologic cancer	9.57e-06	6.44e-05	CcSEcCtD
Etoricoxib—Dermatitis—Etoposide—hematologic cancer	9.56e-06	6.44e-05	CcSEcCtD
Etoricoxib—Headache—Etoposide—hematologic cancer	9.51e-06	6.4e-05	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—hematologic cancer	9.51e-06	6.4e-05	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—hematologic cancer	9.49e-06	6.39e-05	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—hematologic cancer	9.49e-06	6.39e-05	CcSEcCtD
Etoricoxib—Decreased appetite—Prednisone—hematologic cancer	9.46e-06	6.37e-05	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—hematologic cancer	9.45e-06	6.36e-05	CcSEcCtD
Etoricoxib—Rash—Prednisolone—hematologic cancer	9.44e-06	6.36e-05	CcSEcCtD
Etoricoxib—Dermatitis—Prednisolone—hematologic cancer	9.43e-06	6.35e-05	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	9.42e-06	6.34e-05	CcSEcCtD
Etoricoxib—Fatigue—Prednisone—hematologic cancer	9.38e-06	6.31e-05	CcSEcCtD
Etoricoxib—Headache—Prednisolone—hematologic cancer	9.38e-06	6.31e-05	CcSEcCtD
Etoricoxib—Constipation—Prednisone—hematologic cancer	9.3e-06	6.26e-05	CcSEcCtD
Etoricoxib—Muscle spasms—Doxorubicin—hematologic cancer	9.28e-06	6.24e-05	CcSEcCtD
Etoricoxib—Palpitations—Epirubicin—hematologic cancer	9.21e-06	6.2e-05	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—hematologic cancer	9.17e-06	6.17e-05	CcSEcCtD
Etoricoxib—Dizziness—Triamcinolone—hematologic cancer	9.11e-06	6.13e-05	CcSEcCtD
Etoricoxib—Cough—Epirubicin—hematologic cancer	9.1e-06	6.12e-05	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—hematologic cancer	9.09e-06	6.12e-05	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—hematologic cancer	9.09e-06	6.12e-05	CcSEcCtD
Etoricoxib—Infection—Methotrexate—hematologic cancer	9.03e-06	6.08e-05	CcSEcCtD
Etoricoxib—Nausea—Etoposide—hematologic cancer	9.02e-06	6.07e-05	CcSEcCtD
Etoricoxib—Hypertension—Epirubicin—hematologic cancer	9e-06	6.06e-05	CcSEcCtD
Etoricoxib—Feeling abnormal—Prednisone—hematologic cancer	8.97e-06	6.04e-05	CcSEcCtD
Etoricoxib—Asthenia—Betamethasone—hematologic cancer	8.96e-06	6.03e-05	CcSEcCtD
Etoricoxib—Asthenia—Dexamethasone—hematologic cancer	8.96e-06	6.03e-05	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—hematologic cancer	8.92e-06	6e-05	CcSEcCtD
Etoricoxib—Anaemia—Doxorubicin—hematologic cancer	8.92e-06	6e-05	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—hematologic cancer	8.9e-06	5.99e-05	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Prednisone—hematologic cancer	8.9e-06	5.99e-05	CcSEcCtD
Etoricoxib—Nausea—Prednisolone—hematologic cancer	8.89e-06	5.99e-05	CcSEcCtD
Etoricoxib—Arthralgia—Epirubicin—hematologic cancer	8.88e-06	5.98e-05	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—hematologic cancer	8.88e-06	5.98e-05	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—hematologic cancer	8.87e-06	5.97e-05	CcSEcCtD
Etoricoxib—Anxiety—Epirubicin—hematologic cancer	8.85e-06	5.95e-05	CcSEcCtD
Etoricoxib—Pruritus—Dexamethasone—hematologic cancer	8.84e-06	5.95e-05	CcSEcCtD
Etoricoxib—Pruritus—Betamethasone—hematologic cancer	8.84e-06	5.95e-05	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—hematologic cancer	8.83e-06	5.95e-05	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	8.82e-06	5.93e-05	CcSEcCtD
Etoricoxib—Vomiting—Triamcinolone—hematologic cancer	8.76e-06	5.89e-05	CcSEcCtD
Etoricoxib—Rash—Triamcinolone—hematologic cancer	8.68e-06	5.84e-05	CcSEcCtD
Etoricoxib—Dry mouth—Epirubicin—hematologic cancer	8.68e-06	5.84e-05	CcSEcCtD
Etoricoxib—Dermatitis—Triamcinolone—hematologic cancer	8.67e-06	5.84e-05	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—hematologic cancer	8.67e-06	5.83e-05	CcSEcCtD
Etoricoxib—Urticaria—Prednisone—hematologic cancer	8.64e-06	5.82e-05	CcSEcCtD
Etoricoxib—Headache—Triamcinolone—hematologic cancer	8.63e-06	5.81e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Prednisone—hematologic cancer	8.6e-06	5.79e-05	CcSEcCtD
Etoricoxib—Confusional state—Epirubicin—hematologic cancer	8.58e-06	5.78e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Dexamethasone—hematologic cancer	8.55e-06	5.75e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Betamethasone—hematologic cancer	8.55e-06	5.75e-05	CcSEcCtD
Etoricoxib—Palpitations—Doxorubicin—hematologic cancer	8.53e-06	5.74e-05	CcSEcCtD
Etoricoxib—Oedema—Epirubicin—hematologic cancer	8.51e-06	5.73e-05	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—hematologic cancer	8.51e-06	5.73e-05	CcSEcCtD
Etoricoxib—Infection—Epirubicin—hematologic cancer	8.45e-06	5.69e-05	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—hematologic cancer	8.42e-06	5.67e-05	CcSEcCtD
Etoricoxib—Shock—Epirubicin—hematologic cancer	8.37e-06	5.64e-05	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—hematologic cancer	8.35e-06	5.62e-05	CcSEcCtD
Etoricoxib—Thrombocytopenia—Epirubicin—hematologic cancer	8.33e-06	5.61e-05	CcSEcCtD
Etoricoxib—Hypertension—Doxorubicin—hematologic cancer	8.33e-06	5.61e-05	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	8.28e-06	5.58e-05	CcSEcCtD
Etoricoxib—Skin disorder—Epirubicin—hematologic cancer	8.27e-06	5.56e-05	CcSEcCtD
Etoricoxib—Dizziness—Dexamethasone—hematologic cancer	8.26e-06	5.56e-05	CcSEcCtD
Etoricoxib—Dizziness—Betamethasone—hematologic cancer	8.26e-06	5.56e-05	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—hematologic cancer	8.22e-06	5.54e-05	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—hematologic cancer	8.21e-06	5.53e-05	CcSEcCtD
Etoricoxib—Arthralgia—Doxorubicin—hematologic cancer	8.21e-06	5.53e-05	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—hematologic cancer	8.19e-06	5.51e-05	CcSEcCtD
Etoricoxib—Nausea—Triamcinolone—hematologic cancer	8.18e-06	5.51e-05	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	8.16e-06	5.49e-05	CcSEcCtD
Etoricoxib—Anorexia—Epirubicin—hematologic cancer	8.11e-06	5.46e-05	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—hematologic cancer	8.11e-06	5.46e-05	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—hematologic cancer	8.08e-06	5.44e-05	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—hematologic cancer	8.03e-06	5.41e-05	CcSEcCtD
Etoricoxib—Hypersensitivity—Prednisone—hematologic cancer	8.02e-06	5.4e-05	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—hematologic cancer	8e-06	5.39e-05	CcSEcCtD
Etoricoxib—Vomiting—Dexamethasone—hematologic cancer	7.94e-06	5.35e-05	CcSEcCtD
Etoricoxib—Vomiting—Betamethasone—hematologic cancer	7.94e-06	5.35e-05	CcSEcCtD
Etoricoxib—Confusional state—Doxorubicin—hematologic cancer	7.94e-06	5.34e-05	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—hematologic cancer	7.9e-06	5.32e-05	CcSEcCtD
Etoricoxib—Rash—Dexamethasone—hematologic cancer	7.88e-06	5.3e-05	CcSEcCtD
Etoricoxib—Rash—Betamethasone—hematologic cancer	7.88e-06	5.3e-05	CcSEcCtD
Etoricoxib—Oedema—Doxorubicin—hematologic cancer	7.87e-06	5.3e-05	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—hematologic cancer	7.87e-06	5.3e-05	CcSEcCtD
Etoricoxib—Dermatitis—Dexamethasone—hematologic cancer	7.87e-06	5.3e-05	CcSEcCtD
Etoricoxib—Dermatitis—Betamethasone—hematologic cancer	7.87e-06	5.3e-05	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.85e-06	5.28e-05	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—hematologic cancer	7.84e-06	5.28e-05	CcSEcCtD
Etoricoxib—Headache—Betamethasone—hematologic cancer	7.83e-06	5.27e-05	CcSEcCtD
Etoricoxib—Headache—Dexamethasone—hematologic cancer	7.83e-06	5.27e-05	CcSEcCtD
Etoricoxib—Infection—Doxorubicin—hematologic cancer	7.82e-06	5.27e-05	CcSEcCtD
Etoricoxib—Asthenia—Prednisone—hematologic cancer	7.81e-06	5.25e-05	CcSEcCtD
Etoricoxib—Pain—Methotrexate—hematologic cancer	7.78e-06	5.23e-05	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	7.75e-06	5.22e-05	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—hematologic cancer	7.75e-06	5.21e-05	CcSEcCtD
Etoricoxib—Nervous system disorder—Doxorubicin—hematologic cancer	7.72e-06	5.2e-05	CcSEcCtD
Etoricoxib—Thrombocytopenia—Doxorubicin—hematologic cancer	7.71e-06	5.19e-05	CcSEcCtD
Etoricoxib—Pruritus—Prednisone—hematologic cancer	7.7e-06	5.18e-05	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—hematologic cancer	7.7e-06	5.18e-05	CcSEcCtD
Etoricoxib—Skin disorder—Doxorubicin—hematologic cancer	7.65e-06	5.15e-05	CcSEcCtD
Etoricoxib—Dyspnoea—Epirubicin—hematologic cancer	7.59e-06	5.11e-05	CcSEcCtD
Etoricoxib—Somnolence—Epirubicin—hematologic cancer	7.57e-06	5.09e-05	CcSEcCtD
Etoricoxib—Anorexia—Doxorubicin—hematologic cancer	7.51e-06	5.05e-05	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—hematologic cancer	7.49e-06	5.04e-05	CcSEcCtD
Etoricoxib—Dyspepsia—Epirubicin—hematologic cancer	7.49e-06	5.04e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Prednisone—hematologic cancer	7.44e-06	5.01e-05	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—hematologic cancer	7.44e-06	5.01e-05	CcSEcCtD
Etoricoxib—Nausea—Dexamethasone—hematologic cancer	7.42e-06	5e-05	CcSEcCtD
Etoricoxib—Nausea—Betamethasone—hematologic cancer	7.42e-06	5e-05	CcSEcCtD
Etoricoxib—Decreased appetite—Epirubicin—hematologic cancer	7.4e-06	4.98e-05	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Epirubicin—hematologic cancer	7.35e-06	4.95e-05	CcSEcCtD
Etoricoxib—Fatigue—Epirubicin—hematologic cancer	7.34e-06	4.94e-05	CcSEcCtD
Etoricoxib—Pain—Epirubicin—hematologic cancer	7.28e-06	4.9e-05	CcSEcCtD
Etoricoxib—Constipation—Epirubicin—hematologic cancer	7.28e-06	4.9e-05	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—hematologic cancer	7.22e-06	4.86e-05	CcSEcCtD
Etoricoxib—Dizziness—Prednisone—hematologic cancer	7.2e-06	4.84e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—hematologic cancer	7.19e-06	4.84e-05	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.17e-06	4.83e-05	CcSEcCtD
Etoricoxib—Insomnia—Doxorubicin—hematologic cancer	7.12e-06	4.79e-05	CcSEcCtD
Etoricoxib—Dyspnoea—Doxorubicin—hematologic cancer	7.02e-06	4.73e-05	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—hematologic cancer	7.01e-06	4.72e-05	CcSEcCtD
Etoricoxib—Somnolence—Doxorubicin—hematologic cancer	7e-06	4.71e-05	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Epirubicin—hematologic cancer	6.96e-06	4.68e-05	CcSEcCtD
Etoricoxib—Dyspepsia—Doxorubicin—hematologic cancer	6.93e-06	4.67e-05	CcSEcCtD
Etoricoxib—Vomiting—Prednisone—hematologic cancer	6.92e-06	4.66e-05	CcSEcCtD
Etoricoxib—Rash—Prednisone—hematologic cancer	6.86e-06	4.62e-05	CcSEcCtD
Etoricoxib—Dermatitis—Prednisone—hematologic cancer	6.85e-06	4.61e-05	CcSEcCtD
Etoricoxib—Decreased appetite—Doxorubicin—hematologic cancer	6.84e-06	4.61e-05	CcSEcCtD
Etoricoxib—Headache—Prednisone—hematologic cancer	6.82e-06	4.59e-05	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.8e-06	4.58e-05	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—hematologic cancer	6.79e-06	4.57e-05	CcSEcCtD
Etoricoxib—Urticaria—Epirubicin—hematologic cancer	6.76e-06	4.55e-05	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—hematologic cancer	6.73e-06	4.53e-05	CcSEcCtD
Etoricoxib—Constipation—Doxorubicin—hematologic cancer	6.73e-06	4.53e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Epirubicin—hematologic cancer	6.73e-06	4.53e-05	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—hematologic cancer	6.7e-06	4.51e-05	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—hematologic cancer	6.52e-06	4.39e-05	CcSEcCtD
Etoricoxib—Feeling abnormal—Doxorubicin—hematologic cancer	6.49e-06	4.37e-05	CcSEcCtD
Etoricoxib—Nausea—Prednisone—hematologic cancer	6.46e-06	4.35e-05	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Doxorubicin—hematologic cancer	6.44e-06	4.33e-05	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—hematologic cancer	6.43e-06	4.33e-05	CcSEcCtD
Etoricoxib—Hypersensitivity—Epirubicin—hematologic cancer	6.27e-06	4.22e-05	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—hematologic cancer	6.26e-06	4.21e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Doxorubicin—hematologic cancer	6.22e-06	4.19e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—hematologic cancer	6.22e-06	4.19e-05	CcSEcCtD
Etoricoxib—Asthenia—Epirubicin—hematologic cancer	6.11e-06	4.11e-05	CcSEcCtD
Etoricoxib—Pruritus—Epirubicin—hematologic cancer	6.02e-06	4.05e-05	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—hematologic cancer	6.01e-06	4.05e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Epirubicin—hematologic cancer	5.82e-06	3.92e-05	CcSEcCtD
Etoricoxib—Hypersensitivity—Doxorubicin—hematologic cancer	5.8e-06	3.91e-05	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—hematologic cancer	5.78e-06	3.89e-05	CcSEcCtD
Etoricoxib—Rash—Methotrexate—hematologic cancer	5.73e-06	3.86e-05	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—hematologic cancer	5.73e-06	3.86e-05	CcSEcCtD
Etoricoxib—Headache—Methotrexate—hematologic cancer	5.7e-06	3.83e-05	CcSEcCtD
Etoricoxib—Asthenia—Doxorubicin—hematologic cancer	5.65e-06	3.8e-05	CcSEcCtD
Etoricoxib—Dizziness—Epirubicin—hematologic cancer	5.63e-06	3.79e-05	CcSEcCtD
Etoricoxib—Pruritus—Doxorubicin—hematologic cancer	5.57e-06	3.75e-05	CcSEcCtD
Etoricoxib—Vomiting—Epirubicin—hematologic cancer	5.41e-06	3.64e-05	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—hematologic cancer	5.4e-06	3.64e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—hematologic cancer	5.39e-06	3.63e-05	CcSEcCtD
Etoricoxib—Rash—Epirubicin—hematologic cancer	5.37e-06	3.61e-05	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—hematologic cancer	5.36e-06	3.61e-05	CcSEcCtD
Etoricoxib—Headache—Epirubicin—hematologic cancer	5.33e-06	3.59e-05	CcSEcCtD
Etoricoxib—Dizziness—Doxorubicin—hematologic cancer	5.21e-06	3.5e-05	CcSEcCtD
Etoricoxib—Nausea—Epirubicin—hematologic cancer	5.05e-06	3.4e-05	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—hematologic cancer	5.01e-06	3.37e-05	CcSEcCtD
Etoricoxib—Rash—Doxorubicin—hematologic cancer	4.96e-06	3.34e-05	CcSEcCtD
Etoricoxib—Dermatitis—Doxorubicin—hematologic cancer	4.96e-06	3.34e-05	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—hematologic cancer	4.93e-06	3.32e-05	CcSEcCtD
Etoricoxib—Nausea—Doxorubicin—hematologic cancer	4.68e-06	3.15e-05	CcSEcCtD
Etoricoxib—CYP1A2—Metabolism—NCOA3—hematologic cancer	2.01e-06	2.36e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ADCY7—hematologic cancer	2.01e-06	2.36e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.01e-06	2.35e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTPN11—hematologic cancer	2e-06	2.35e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NUP214—hematologic cancer	2e-06	2.34e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CA9—hematologic cancer	1.99e-06	2.34e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ACP5—hematologic cancer	1.99e-06	2.34e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EP300—hematologic cancer	1.99e-06	2.33e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CD44—hematologic cancer	1.98e-06	2.33e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NQO1—hematologic cancer	1.98e-06	2.33e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.98e-06	2.32e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NCOR1—hematologic cancer	1.97e-06	2.31e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GSTM1—hematologic cancer	1.97e-06	2.31e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.97e-06	2.31e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.96e-06	2.29e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—MTR—hematologic cancer	1.96e-06	2.29e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.94e-06	2.28e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CREB1—hematologic cancer	1.94e-06	2.27e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—SRC—hematologic cancer	1.93e-06	2.27e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.92e-06	2.25e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ENO2—hematologic cancer	1.92e-06	2.25e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BAD—hematologic cancer	1.92e-06	2.25e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BRAF—hematologic cancer	1.91e-06	2.24e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOTCH1—hematologic cancer	1.9e-06	2.23e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL2—hematologic cancer	1.9e-06	2.22e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6R—hematologic cancer	1.89e-06	2.22e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CREBBP—hematologic cancer	1.89e-06	2.21e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYCS—hematologic cancer	1.88e-06	2.2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—IDH1—hematologic cancer	1.87e-06	2.2e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	1.87e-06	2.19e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—hematologic cancer	1.86e-06	2.19e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTT1—hematologic cancer	1.86e-06	2.18e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD80—hematologic cancer	1.86e-06	2.18e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—hematologic cancer	1.86e-06	2.18e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KIT—hematologic cancer	1.86e-06	2.18e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.85e-06	2.17e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TXN—hematologic cancer	1.85e-06	2.17e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.85e-06	2.17e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—MTHFR—hematologic cancer	1.85e-06	2.17e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.83e-06	2.15e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CD44—hematologic cancer	1.83e-06	2.14e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NQO1—hematologic cancer	1.83e-06	2.14e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTPN11—hematologic cancer	1.82e-06	2.14e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SDC1—hematologic cancer	1.82e-06	2.13e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.81e-06	2.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CD44—hematologic cancer	1.81e-06	2.12e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NQO1—hematologic cancer	1.81e-06	2.12e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAP2K1—hematologic cancer	1.8e-06	2.11e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CD—hematologic cancer	1.79e-06	2.1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—MAPK3—hematologic cancer	1.78e-06	2.09e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.77e-06	2.08e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MAPK3—hematologic cancer	1.77e-06	2.08e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CREB1—hematologic cancer	1.77e-06	2.07e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BRAF—hematologic cancer	1.75e-06	2.05e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—MTHFR—hematologic cancer	1.74e-06	2.04e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.74e-06	2.04e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.74e-06	2.04e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYCS—hematologic cancer	1.73e-06	2.03e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6R—hematologic cancer	1.72e-06	2.02e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—hematologic cancer	1.72e-06	2.02e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CREBBP—hematologic cancer	1.72e-06	2.02e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.72e-06	2.01e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.71e-06	2.01e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGF2—hematologic cancer	1.71e-06	2.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYCS—hematologic cancer	1.71e-06	2.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.7e-06	2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.69e-06	1.99e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.69e-06	1.99e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3R1—hematologic cancer	1.69e-06	1.98e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.68e-06	1.97e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTP1—hematologic cancer	1.65e-06	1.94e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.65e-06	1.94e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAP2K1—hematologic cancer	1.64e-06	1.93e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JAK2—hematologic cancer	1.64e-06	1.93e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.64e-06	1.92e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CD—hematologic cancer	1.63e-06	1.91e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.63e-06	1.91e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MDM2—hematologic cancer	1.6e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.6e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—hematologic cancer	1.6e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NUP98—hematologic cancer	1.6e-06	1.87e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCB1—hematologic cancer	1.57e-06	1.84e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGF2—hematologic cancer	1.56e-06	1.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MTOR—hematologic cancer	1.56e-06	1.83e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CB—hematologic cancer	1.56e-06	1.83e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—hematologic cancer	1.55e-06	1.82e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.55e-06	1.82e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.55e-06	1.82e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CD44—hematologic cancer	1.55e-06	1.81e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NQO1—hematologic cancer	1.55e-06	1.81e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3R1—hematologic cancer	1.54e-06	1.81e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NUP214—hematologic cancer	1.54e-06	1.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.53e-06	1.8e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.52e-06	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NCOR1—hematologic cancer	1.52e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTM1—hematologic cancer	1.52e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.51e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MTR—hematologic cancer	1.51e-06	1.77e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.51e-06	1.77e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.51e-06	1.77e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—JAK2—hematologic cancer	1.5e-06	1.76e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.48e-06	1.74e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—hematologic cancer	1.47e-06	1.72e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—hematologic cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1B—hematologic cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYCS—hematologic cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MDM2—hematologic cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.46e-06	1.71e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.45e-06	1.71e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CREBBP—hematologic cancer	1.44e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.44e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.44e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—hematologic cancer	1.43e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—hematologic cancer	1.43e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.43e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CB—hematologic cancer	1.42e-06	1.67e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MTOR—hematologic cancer	1.42e-06	1.67e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD4—hematologic cancer	1.42e-06	1.67e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.4e-06	1.65e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.4e-06	1.64e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.4e-06	1.64e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—hematologic cancer	1.4e-06	1.64e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JUN—hematologic cancer	1.39e-06	1.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.39e-06	1.63e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.39e-06	1.63e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CD—hematologic cancer	1.37e-06	1.6e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—hematologic cancer	1.36e-06	1.6e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CREBBP—hematologic cancer	1.36e-06	1.59e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—hematologic cancer	1.35e-06	1.58e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ALB—hematologic cancer	1.35e-06	1.58e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTEN—hematologic cancer	1.35e-06	1.58e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.34e-06	1.58e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1B—hematologic cancer	1.34e-06	1.57e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK8—hematologic cancer	1.32e-06	1.55e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.31e-06	1.53e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—hematologic cancer	1.3e-06	1.53e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3R1—hematologic cancer	1.29e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.29e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CD—hematologic cancer	1.29e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EP300—hematologic cancer	1.29e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ALB—hematologic cancer	1.27e-06	1.49e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SRC—hematologic cancer	1.25e-06	1.47e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.25e-06	1.46e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.24e-06	1.45e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—hematologic cancer	1.23e-06	1.45e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTEN—hematologic cancer	1.23e-06	1.44e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.23e-06	1.44e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.22e-06	1.43e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—hematologic cancer	1.22e-06	1.43e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3R1—hematologic cancer	1.22e-06	1.43e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—hematologic cancer	1.21e-06	1.41e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—hematologic cancer	1.2e-06	1.41e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—hematologic cancer	1.2e-06	1.41e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—hematologic cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CD44—hematologic cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CB—hematologic cancer	1.19e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.19e-06	1.39e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.19e-06	1.39e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.18e-06	1.39e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EP300—hematologic cancer	1.17e-06	1.38e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MAPK3—hematologic cancer	1.15e-06	1.35e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SRC—hematologic cancer	1.14e-06	1.34e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.13e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYCS—hematologic cancer	1.13e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CB—hematologic cancer	1.12e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—hematologic cancer	1.12e-06	1.31e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—hematologic cancer	1.12e-06	1.31e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—hematologic cancer	1.1e-06	1.29e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—hematologic cancer	1.1e-06	1.29e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.08e-06	1.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAPK3—hematologic cancer	1.05e-06	1.23e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.05e-06	1.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.05e-06	1.23e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.04e-06	1.22e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—hematologic cancer	1.03e-06	1.21e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.03e-06	1.21e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTEN—hematologic cancer	1.03e-06	1.21e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—hematologic cancer	1.02e-06	1.2e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—hematologic cancer	1.02e-06	1.2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.95e-07	1.17e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CD—hematologic cancer	9.93e-07	1.16e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—EP300—hematologic cancer	9.82e-07	1.15e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ALB—hematologic cancer	9.8e-07	1.15e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTEN—hematologic cancer	9.69e-07	1.14e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CREBBP—hematologic cancer	9.63e-07	1.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CREBBP—hematologic cancer	9.55e-07	1.12e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—hematologic cancer	9.51e-07	1.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—hematologic cancer	9.44e-07	1.11e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCB1—hematologic cancer	9.42e-07	1.1e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3R1—hematologic cancer	9.37e-07	1.1e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—EP300—hematologic cancer	9.24e-07	1.08e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.23e-07	1.08e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—hematologic cancer	9.2e-07	1.08e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOR1—hematologic cancer	9.15e-07	1.07e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTM1—hematologic cancer	9.15e-07	1.07e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	9.13e-07	1.07e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	9.05e-07	1.06e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ALB—hematologic cancer	9.01e-07	1.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ALB—hematologic cancer	8.94e-07	1.05e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.8e-07	1.03e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—hematologic cancer	8.8e-07	1.03e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—hematologic cancer	8.67e-07	1.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CB—hematologic cancer	8.65e-07	1.01e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	8.62e-07	1.01e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	8.55e-07	1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—hematologic cancer	8.42e-07	9.87e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CREBBP—hematologic cancer	8.16e-07	9.57e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MTHFR—hematologic cancer	8.08e-07	9.48e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—hematologic cancer	8.02e-07	9.41e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.96e-07	9.34e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	7.89e-07	9.25e-06	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—hematologic cancer	7.77e-07	9.11e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.74e-07	9.07e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—hematologic cancer	7.68e-07	9.01e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ALB—hematologic cancer	7.64e-07	8.96e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTEN—hematologic cancer	7.48e-07	8.77e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	7.3e-07	8.57e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—hematologic cancer	7.26e-07	8.52e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—EP300—hematologic cancer	7.13e-07	8.36e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—hematologic cancer	7.08e-07	8.31e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTEN—hematologic cancer	6.88e-07	8.07e-06	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—hematologic cancer	6.84e-07	8.02e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTEN—hematologic cancer	6.82e-07	8e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.79e-07	7.97e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.74e-07	7.91e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—EP300—hematologic cancer	6.56e-07	7.69e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—EP300—hematologic cancer	6.5e-07	7.63e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.3e-07	7.38e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.97e-07	7e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—hematologic cancer	5.93e-07	6.96e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ALB—hematologic cancer	5.89e-07	6.91e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTEN—hematologic cancer	5.83e-07	6.83e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.64e-07	6.61e-06	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—hematologic cancer	5.59e-07	6.55e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—EP300—hematologic cancer	5.56e-07	6.52e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—hematologic cancer	5.27e-07	6.19e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.2e-07	6.1e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.85e-07	5.69e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	4.81e-07	5.64e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTEN—hematologic cancer	4.5e-07	5.27e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—hematologic cancer	4.31e-07	5.05e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—EP300—hematologic cancer	4.29e-07	5.03e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	4.11e-07	4.82e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—hematologic cancer	3.96e-07	4.65e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—hematologic cancer	3.93e-07	4.61e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—hematologic cancer	3.36e-07	3.94e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.17e-07	3.72e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—hematologic cancer	2.59e-07	3.04e-06	CbGpPWpGaD
